CNTO2476, human umbilical tissue-derived cells for macular degeneration

CNTO2476 are human umbilical tissue-derived cells  which were subretinally administered to assess their safety and efficacy in treatment of macular degeneration resulting from age-related macular degeneration (AMD) or retinitis pigmentosa (RP). In RP patients there was no evidence of immunogenicity. Some surgery-related adverse events were reported in the trial in AMD patients; as a result, the surgical procedure was modified. Half of the AMD patients demonstrated improved vision.